Discover

AMGN
Amgen Inc.
361.33
1 x 361.89
1 x 360.89
bid
ask
-
0.79
0.22%
1 @ 06:19 AM
362.83 +1.50 (0.42%)
Ytd10.39%
1y24.37%
357.89
day range
364.00
269.77
52 week range
391.29
Open362.10Prev Close362.12Low357.89High364.00Mkt Cap195.01B
Vol1.95MAvg Vol2.75MEPS14.38P/E25.13Forward P/E15.40
Beta0.42Short Ratio4.42Inst. Own85.21%Dividend10.08Div Yield2.78
Ex Div Date05-15Earning08-0450-d Avg340.81200-d Avg334.841yr Est352.77

AMGN News

Judge blocks Colorado's first-of-its-kind price cap on Amgen's Enbrel
reuters.com
Judge blocks Colorado's first-of-its-kind price cap on Amgen's Enbrel

A federal judge on Wednesday blocked Colorado ​from capping the price of Amgen's blockbuster arthrit

Amgen or Biogen: Which Biotech Stock Appears Better Poised?
zacks.com
Amgen or Biogen: Which Biotech Stock Appears Better Poised?

AMGN stands out compared to Biogen given its broader product portfolio, pipeline depth and steadier

Weight Loss ETFs Poised to Rally as Medicare Greenlights GLP-1 Coverage
zacks.com
Weight Loss ETFs Poised to Rally as Medicare Greenlights GLP-1 Coverage

Medicare's new GLP-1 coverage could expand access to weight-loss drugs, making ETFs a diversified wa

Micron, Palo Alto, Apple And A Health Care Stock On CNBC’s ‘Final Trades’
benzinga.com
Micron, Palo Alto, Apple And A Health Care Stock On CNBC’s ‘Final Trades’

CNBC Final trades: Lebenthal picks Micron, Snipe chooses Palo Alto, Brown expects Apple's good s

Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know
zacks.com
Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know

Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth expl

Alphabet Just Joined the Dow Jones Industrial Average. 3 Dow Dividend Stocks to Buy Now.
fool.com
Alphabet Just Joined the Dow Jones Industrial Average. 3 Dow Dividend Stocks to Buy Now.

Cisco Systems is on a roll with its AI-powered platform. Coca-Cola saw volume growth in each of its

Medical journal retracts paper on Amgen's Tavneos drug trial after FDA findings
reuters.com
Medical journal retracts paper on Amgen's Tavneos drug trial after FDA findings

The New England Journal of Medicine on Monday retracted an article on a pivotal clinical trial that

Apollo To Drive Quantinuum Revenue Growth Of 128% Until 2031, Say Bullish Analysts
benzinga.com
Apollo To Drive Quantinuum Revenue Growth Of 128% Until 2031, Say Bullish Analysts

Shares of Quantinuum slide after rallying since IPO. Analysts weigh in.

Viridian Secures First FDA Approval, Sets Up Challenge To Amgen's Tepezza For Thyroid Eye Disease
benzinga.com
Viridian Secures First FDA Approval, Sets Up Challenge To Amgen's Tepezza For Thyroid Eye Disease

The U.S. Food and Drug Administration on Friday approved Viridian Therapeutics Inc.'s (NASDAQ:VRDN)

Viridian Secures First FDA Approval, Sets Up Challenge To Amgen's Tepezza For Thyroid Eye Disease
benzinga.com
Viridian Secures First FDA Approval, Sets Up Challenge To Amgen's Tepezza For Thyroid Eye Disease

FDA approves Viridian Therapeutics' Lumvoa for thyroid eye disease. Immediate commercial launch

European Regulator Calls for Amgen's Tavneos to Have Authorization Revoked
wsj.com
European Regulator Calls for Amgen's Tavneos to Have Authorization Revoked

The committee is recommending that no new patients start treatment with Tavneos and that existing pa

EMA recommends revoking marketing authorisation for Amgen's rare-disease drug
reuters.com
EMA recommends revoking marketing authorisation for Amgen's rare-disease drug

The European Medicines Agency on ‌Friday recommended revoking the marketing authorisation for Amgen'

Less Volume, More Premium: Post-Ozempic Economics Are Killing The Quantity Model
benzinga.com
Less Volume, More Premium: Post-Ozempic Economics Are Killing The Quantity Model

As millions take GLP-1 drugs, packaged food giants face declining volumes while protein brands and s

W.P. Carey To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Tuesday
benzinga.com
W.P. Carey To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Tuesday

Top analysts changed ratings on top names, including Sunrun, enGene Therapeutics, Camp4 Therapeutics

benzinga.com
Mizuho Maintains Neutral on Amgen, Raises Price Target to $303

Mizuho analyst Salim Syed maintains Amgen (NASDAQ:AMGN) with a Neutral and raises the price targe

benzinga.com
Morgan Stanley Maintains Equal-Weight on Amgen, Raises Price Target to $340

Morgan Stanley analyst Terence Flynn maintains Amgen (NASDAQ:AMGN) with a Equal-Weight and raises

benzinga.com
Reported June 1, 2026: European Commission Approves Amgen's IMDYLLTRA For The Treatment Of Extensive

Approval Based Upon Phase 3 DeLLphi-304 Trial Demonstrating 40% Reduction in Risk of Death with IMDY